TABLE 2.
CSF PET agreement in studies reporting individual biomarkers and biomarker ratios using automated assay platforms
| Individual CSF biomarkers | CSF biomarker ratios | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Study objective | Platform | Measure | p‐tau | t‐tau | Aβ1‐42 | Aβ1‐40 | p‐tau/Aβ42 | t‐tau/ Aβ42 | Aβ1‐42/Aβ1‐40 |
| Schindler et al. 201823 | To measure relationship between CSF biomarkers and amyloid PET | Elecsys | PPA | 82% | 68% | 90% | 60% | 92% | 92% | 96% |
| NPA | 76% | 83% | 73% | 58% | 89% | 85% | 82% | |||
| OPA | 78% | 79% | 77% | 59% | 89% | 87% | 86% | |||
| AUC | 0.84 | 0.81 | 0.85 | 0.60 | 0.96 | 0.95 | 0.93 | |||
| Doecke et al. 202014 | To measure concordance between CSF biomarkers and pathological AD via PET imaging | Elecsys | PPA | 81% | 86% | 81% | 90% | 83% | 90% | |
| NPA | 77% | 66% | 81% | 91% | 97% | 90% | ||||
| OPA | 79% | 75% | 81% | 91% | 91% | 90% | ||||
| AUC | 0.84 | 0.81 | 0.86 | 0.94 | 0.94 | 0.94 | ||||
| Willemse et al. 2020 (abstract) 24 | To measure CSF biomarkers compared to amyloid PET imaging | Elecsys | PPA | 91% | 96% | 96% | ||||
| NPA | 75% | 89% | 80% | |||||||
| OPA | ||||||||||
| AUC | ||||||||||
| To measure CSF biomarkers compared to amyloid PET imaging | Lumipulse | PPA | 91% | 97% | 99% | |||||
| NPA | 73% | 91% | 83% | |||||||
| OPA | ||||||||||
| AUC | ||||||||||
| Keshaven et al. 202021 | To measure concordance between CSF biomarkers and PET imaging | Lumipulse | PPA | 100% | 54% | 100% | 100% | 92% | 100% | |
| NPA | 66% | 82% | 74% | 94% | 90% | 94% | ||||
| OPA | ||||||||||
| AUC | 0.879 | 0.665 | 0.891 | 0.966 | 0.955 | 0.966 | ||||
| Alcolea et al. 201920 | To determine cut‐offs between PET and CSF biomarkers | Lumipulse | PPA | 80% | 75% | 95% | 93% | 81% | 88% | |
| NPA | 83% | 83% | 51% | 80% | 83% | 77% | ||||
| OPA | 81% | 78% | 79% | 88% | 82% | 84% | ||||
| AUC | 0.84 | 0.80 | 0.76 | 0.59 | 0.88 | 0.87 | 0.86 | |||
| Kaplow et al. 202015 | To determine concordance of CSF biomarker ratios with amyloid PET (test cohort A/B) | Lumipulse | PPA | 74.1% | 98.8% | 97.5% | ||||
| NPA | 89.8% | 75.5% | 89.8% | |||||||
| OPA | 80.0% | 90.0% | 94.6% | |||||||
| AUC | 0.87 | 0.92 | 0.95 | |||||||
| Moon et al. 202122 | To evaluate concordance of CSF biomarkers and PET imaging | Lumipulse | PPA | 79.5% | 59.0% | 79.5% | 84.6% | 84.6% | 84.6% | |
| NPA | 78.6% | 89.3% | 88.1% | 92.9% | 88.1% | 91.7% | ||||
| OPA | ||||||||||
| AUC | 0.839 | 0.791 | 0.857 | 0.840 | 0.842 | 0.856 | ||||
Notes:
PPA: positive percent agreement (defined as the percent of PET‐positive individuals also positive by a CSF biomarker measure).
NPA: negative percent agreement (defined as the percent of PET‐negative individuals also negative by a CSF biomarker measure).
OPA: overall percent agreement (defined as the sum of the PET‐positive individuals also positive by a CSF biomarker measure and the PET‐negative individuals also negative by a CSF biomarker measure divided by the entire cohort size.
AUC: area under the receiver operator curve for PPA on the Y axis and 1 – NPA on the X axis; AUC 1 represents a ‘perfect test,’ where there is 100% agreement between CSF biomarker and PET imaging results.
Abbreviations: Aβ, amyloid beta; AD, Alzheimer's disease; CSF, cerebrospinal fluid; LP, lumbar puncture; PET, positron emission tomography; p‐tau, phosphorylated tau; t‐tau, total tau.